Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects. Following the upgrade, the current consensus from CorMedix's four analysts is for revenues of US$111m in 2025 which - if met - would reflect a sizeable increase on its sales over the past 12 months. The losses are expected to disappear over the next year or so, with forecasts for a profit of US$0.45 per share next year. Before this latest update, the analysts had been forecasting revenues of US$100m and earnings per share (EPS) of US$0.18 in 2025. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates. View our latest analysis for CorMedix Despite these upgrades, the analysts have not made any major changes to their price target of US$14.25, suggesting that the higher estimates are not likely
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. to Participate in the Truist Securities BioPharma SymposiumGlobeNewswire
- CorMedix Inc. (NASDAQ: CRMD) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. (NASDAQ: CRMD) had its price target raised by analysts at Needham & Company LLC from $10.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
CRMD
Earnings
- 10/30/24 - Beat
CRMD
Sec Filings
- 10/30/24 - Form 10-Q
- 10/30/24 - Form 8-K
- 10/8/24 - Form DEF
- CRMD's page on the SEC website